Table 3 Baseline characteristics of patients
Characteristics | Alegorides,2020 | Darson,2017 | Dixon,2016 | Elterman,2022 | Fernández-Guzmán,2022 | Ines,2021 | Ines*,2021 | Ines#,2021 | McVary,2016 | Wasserbauer,2021 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
No. of patients | 62 | 131 | 65 | 229 | 137 | 140 | 26 | 13 | 136 | 76 | |
Age (years) | 64.3 ± 11.9 | 70.9 ± 9.4 | 66.6 ± 7.7 | 67.3 | 65.31 | 64.5 ± 8.4 | 60.4 ± 9.2 | 67.2 ± 8.2 | 63 ± 7.1 | 65.3 ± 7.1 | |
Median lobe (%) | 29 (46.7%) | 54 (41.2%) | 14 (21.5%) | 126 (55%) | 64 (46.7%) | 100 (55.9%) | 42 (30.9%) | NA | |||
Bladder catheter (%) | 8 (12.9%) | NA | NA | 16 (7.0%) | NA | NA | NA | 6 (7.9%) | |||
Prostate volume (ml) | 54.3 ± 28.4 | 45.1 ± 23.4 | 48.6 ± 20.5 | 71.5 | 50.38 ± 18.45 | 47.6 ± 13 | 25.2 ± 2.8 | 93.6 ± 9.9 | 45.8 ± 13 | 61.8 ± 29.2 | |
PSA (ng/L) | 2.9 ± 2.7 | 3.5 ± 5.6 | 3.9 ± 4.2 | NA | 2.4 | 2.5 ± 2.3 | 0.8 ± 0.9 | 12.2 ± 11.7 | 2.1 ± 1.5 | 3.5 ± 2.8 | |
IPSS | 19.9 ± 6.3 | 19.5 ± 6.6 | 21.6 ± 5.5 | NA | 21 ± 4.63 | 18.7 ± 6.8 | 21.5 ± 6.9 | 18.4 ± 5.5 | 22 ± 4.8 | 19.1 ± 6.3 | |
Qol | NA | 4.3 ± 1.2 | 4.3 ± 1.1 | NA | 4.09 ± 0.93 | 4.4 ± 1.3 | 4.8 ± 1.4 | 4.1 ± 0.9 | 4.4 ± 1.1 | 4 ± 1.1 | |
PVR (ml) | 78.9 ± 88.9 | 216.8 ± 286.6 | 92.4 ± 77.3 | NA | NA | 34.9 ± 64.2 | 18 ± 49.8 | 30.2 ± 46.8 | 82 ± 51.5 | 67.7 ± 98.1 | |
Qmax (ml/s) | 11.0 ± 3.4 | 8.6 ± 4.9 | 7.9 ± 3.2 | NA | 8.98 ± 4.06 | 9.3 ± 2.8 | 9.1 ± 2.8 | 6.2 ± 2.7 | 9.9 ± 2.3 | 8.8 ± 3.7 | |
BPH II | NA | NA | 6.8 ± 2.8 | NA | NA | NA | NA | NA | 6.3 ± 2.8 | NA | |
IIEF-EF | NA | NA | 13.3 ± 12 | NA | NA | 15.6 ± 8.6 | 18.6 ± 8.4 | 14.1 ± 9.3 | 17.2 ± 10.3 | NA | |
MSHQ-EjD | 8.6 ± 4.9 | NA | 5.9 ± 4.8 | NA | NA | NA | NA | NA | 7.8 ± 4.1 | NA | |
MSHQ-bother | 2.0 ± 1.7 | NA | 2.3 ± 2.3 | NA | NA | NA | NA | NA | 2.6 ± 1.7 | NA | |